DAFNA Capital Management’s Prevail Therapeutics PRVL Stock Holding History
Bought
Maintained
Sold
DAFNA Capital Management's PRVL Position: Q1 2021 in Review
DAFNA Capital Management sold out of Prevail Therapeutics (PRVL) in Q1 2021, closing a stake of 75,000 shares — an estimated $1.73M sold.
DAFNA Capital Management first reported a position in PRVL in Q2 2019 and held it in 7 quarters. The position peaked at $1.73M in Q4 2020. 0 funds tracked by Wall St. Rank hold PRVL as of Q1 2021.
- DAFNA Capital Management reported no remaining Prevail Therapeutics position as of Q1 2021 after selling out during the quarter.
- DAFNA Capital Management sold 75,000 Prevail Therapeutics shares in Q1 2021, an estimated $1.73M.
- DAFNA Capital Management first reported a position in Prevail Therapeutics in Q2 2019 and held it in 7 quarters.
- DAFNA Capital Management's Prevail Therapeutics position peaked at $1.73M in Q4 2020.
- 0 funds tracked by Wall St. Rank held Prevail Therapeutics as of Q1 2021.
Based on DAFNA Capital Management's 13F filing for Q1 2021, filed 17 May 2021.